-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma

Sponsor: Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, both are Johnson & Johnson companies, and Sanofi.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Lymphoid Leukemias, ALL, Education, Diseases, Treatment Considerations, Lymphoid Malignancies, Adverse Events
Friday, December 6, 2024: 7:00 PM-10:00 PM
Room 30 (San Diego Convention Center)
Chair:
Ola Landgren, ARRAY(0xdc14674)
Disclosures:
Landgren: Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Merck: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Theradex: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees.; Adaptive: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Membership on independent data monitoring committees.
Speakers:
Katja C. Weisel, MD, Department of Oncology, Hematology and BMT, University Medical Center of Hamburg-Eppendorf and Cristina Gasparetto, MD, Duke University Medical Center
Disclosures:
Weisel: Adaptive Biotechnologies: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria, Other: Research grant to institution; Takeda: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Roche Pharma: Consultancy, Honoraria; AstraZeneca: Honoraria; Novartis: Honoraria; Amgen: Consultancy, Honoraria, Other: Research grant to institution; AbbVie: Other: Research grant to institution; Bristol Myers Squibb/Celgene: Consultancy, Honoraria, Other: Research grant to institution; BeiGene: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria; GlaxoSmithKline: Consultancy, Honoraria, Other: Research grant to institution; Janssen: Consultancy, Honoraria, Other: Research grant to institution; Menarini: Consultancy, Honoraria; Oncopeptides: Consultancy, Honoraria; Stemline: Honoraria; Regeneron: Consultancy.

The live portion of this activity will be presented as a 2.0-hour Friday Satellite Symposium (FSS). The activity is designed to highlight and test participants on the most clinically relevant data in NDMM, provide expert guidance on the interpretation of core concepts, and forecast the clinical impact of recent data sets. The activity will integrate a series of How We Do It® panel discussions alongside didactic presentations. To further enhance the integration of recent data into practice, the program will
feature an interactive question-and-answer session with faculty throughout the
activity to emphasize areas of educational need, highlighting areas of debate, and
illustrating the application of new data in defined clinical situations. To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations